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ADP-ribosylation is a posttranslational modiﬁcation that modu-
lates the functions of many target proteins. We previously showed
that the fungal toxin brefeldin A (BFA) induces the ADP-ribosyla-
tion of C-terminal–binding protein-1 short-form/BFA–ADP-ribosy-
lation substrate (CtBP1-S/BARS), a bifunctional protein with roles
in the nucleus as a transcription factor and in the cytosol as a reg-
ulator of membrane ﬁssion during intracellular trafﬁcking and mi-
totic partitioning of the Golgi complex. Here, we report that ADP-
ribosylation of CtBP1-S/BARS by BFA occurs via a nonconventional
mechanism that comprises two steps: (i) synthesis of a BFA–ADP-
ribose conjugate by the ADP-ribosyl cyclase CD38 and (ii) covalent
binding of the BFA–ADP-ribose conjugate into the CtBP1-S/BARS
NAD+-binding pocket. This results in the locking of CtBP1-S/BARS
in a dimeric conformation, which prevents its binding to interactors
known to be involved in membrane ﬁssion and, hence, in the in-
hibition of the ﬁssion machinery involved in mitotic Golgi partition-
ing. As this inhibition may lead to arrest of the cell cycle in G2, these
ﬁndings provide a strategy for the design of pharmacological block-
ers of cell cycle in tumor cells that express high levels of CD38.
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The modiﬁcation of proteins by mono-ADP-ribosylation in-volves the transfer of a single ADP-ribose (ADPR) from
NAD+ to speciﬁc amino acids in target proteins by mono-ADP-
ribosyltransferases (1–3). The mono-ADP-ribosylation reaction
was characterized ﬁrst in bacteria, in which ADP-ribosyl-
transferases have roles as toxins [e.g., cholera and pertussis
toxins (1)]. More recently, this reaction was also characterized
in eukaryotic cells, in which a large group of mono-ADP-
ribosyltransferases has been identiﬁed and proposed to be in-
volved in the regulation of numerous physiological functions
(4). We previously reported that the fungal toxin brefeldin A
(BFA), a macrocyclic lactone used widely in studies of mem-
brane trafﬁcking (see below), induces the ADP-ribosylation of
the C-terminal–binding protein-1 short-form/BFA–ADP-ribosy-
lation substrate (CtBP1-S/BARS; for brevity, BARS) with high
afﬁnity and selectivity, and of the glycolytic enzyme GAPDH
with much lower efﬁciency (5, 6). Here, we explore the molecular
mechanisms and possible function of the BFA-dependent ADP-
ribosylation of BARS.
BARS is structurally related to the D2-hydroxy acid de-
hydrogenase family and is a member of the CtBP family (7). It is
involved in two processes, one in the cell cytosol and the other in
the nucleus (7). In the cytosol, BARS controls the membrane-
ﬁssion machinery that drives the formation of post-Golgi carriers
(8, 9), endocytic ﬂuid-phase carriers (8, 10), and coatomer pro-
tein I (COP1)-coated vesicles (11), and the partitioning of Golgi
during mitosis (12, 13). In the nucleus, members of the CtBP
protein family act as transcription corepressors, thus regulating
numerous cellular functions, including epithelial differentiation,
tumorigenesis, and apoptosis (14, 15). It remains unclear whether
the nuclear and cytoplasmic functions of BARS are related.
BFA is a toxin produced by several fungi (e.g., Eupenicillium
brefeldianum, Alternaria carthami), and its role in nature is not
well understood. It has been shown to induce necrosis of the
leaf tissue in safﬂower (leaf spot diseases), probably to facilitate
colonization by the fungi (16). As a research tool, BFA has been
characterized extensively and used to analyze the mechanisms of
membrane transport. Its best-known effect is the induction of the
formation of numerous long tubules from the Golgi complex,
which then fuse to the endoplasmic reticulum (ER), thereby
mediating the redistribution of resident Golgi proteins into the
ER (17) and hence causing a rapid and reversible block of se-
cretion (17). At the molecular level, this effect of BFA is me-
diated by the inhibition of the GTPase exchange factor acting on
the small Ras-like GTPase ARF, and by the release of ARF from
the Golgi complex along with a set of proteins regulated by ARF
(18). Whether the effects of BFA on Golgi tubulation and dis-
assembly are linked to those of the ADP-ribosylation of BARS
remains unclear (7). It has been proposed that ADP-ribosylation
of BARS contributes to the disassembly of the Golgi complex, at
least under certain conditions (19), by inhibiting the ﬁssion of
Golgi tubules (7, 20). However, the molecular mechanisms and
the functional effects of BARS ADP-ribosylation remain to
be characterized.
In the present study, we show that BFA-induced ADP-
ribosylation is a noncanonical two-step process that involves the
enzymatic synthesis of a previously uncharacterized BFA-ADPR
conjugate (BAC) by the ADP-ribosyl cyclase CD38. The for-
mation of BAC then is followed by covalent binding of BAC
to the NAD+-binding pocket of BARS. This ADP-ribosylation
induces a change in the conformation of BARS that precludes its
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binding to key interactors and inhibits the BARS ﬁssion activity
in mitotic Golgi partitioning. Because partitioning of the Golgi
complex is required for completion of the cell cycle, these ﬁnd-
ings carry pharmacological implications for cancer treatment.
Results
Transfer of ADP-Ribose to BARS Is Mediated by Formation of a BAC.
To investigate the molecular mechanisms of the BFA-induced
ADP-ribosylation reaction, we incubated a mixture of rat brain
membranes and cytosol with BFA and [32P]-NAD+ for 1 h at 37 °C
(Fig. 1A, one step). As expected, this complete mixture gave rise
to ADP-ribosylation of the BARS in the cytosol (5, 6). Next, we
carried out the reaction in two steps, using different mixtures. For
the ﬁrst step, we incubated the rat brain membranes (as a source
of the enzyme that catalyzes the ADP-ribosylation reaction)
with NAD+ without or with BFA, and NAD+ and BFA without
the membranes. The samples then were centrifuged to remove
the membranes and ultraﬁltered (with a 3,000-Da cutoff). In the
second step, we mixed this ultraﬁltrate with cytosol. Here, the ul-
traﬁltrate that had been generated in the presence of the mem-
branes, NAD+, and BFA (but not the ultraﬁltrate produced in the
absence of the membranes or of BFA) resulted in ADP-ribosyla-
tion of the cytosolic BARS, as shown by denaturing SDS/PAGE
analysis (Fig. 1A, two steps). This indicates that in the presence of
BFA and NAD+, a membrane-bound enzyme catalyzes the syn-
thesis of a soluble BFA/NAD+ derivative that then leads to the
modiﬁcation of BARS.
We thus set out to isolate this active derivative by HPLC using
ADP-ribosylation of cytosolic BARS for its detection (Fig. 1 B
and C) (5, 6). The derivative showed an HPLC elution proﬁle
that did not match the elution times of NAD+ and its known
analogs, i.e., ADPR, cyclic ADPR (cADPR), nicotinamide ad-
enine dinucleotide phosphate, and nicotinic acid adenine di-
nucleotide phosphate. Next, to characterize the active derivative
further, we sought to synthesize it using other ADPR-containing
molecules as substrates, instead of NAD+. Strikingly, the active
derivative also was synthesized in the presence of cADPR (albeit
with lower efﬁciency; SI Materials and Methods) but not ADPR.
This ﬁnding offered a clue toward determining the molecular
mechanisms of the generation of this BFA/NAD+ derivative.
Both NAD+ and cADPR are substrates of a class of enzymes known
as ADP-ribosyl cyclases. These cyclases catalyze the conversion of
NAD+ to cADPR through cleavage of the nicotinamide–ribose
glycosidic bond and the formation of an enzyme-stabilized ADP-
ribosyl–oxocarbenium ion intermediate (Fig. S1) (21, 22). This in-
termediate is a good electrophile and can react with water to form
ADPR, or intramolecularly, with the N1 atom of the purinic ring of
the adenine moiety of NAD+, to form cADPR. In addition, the
same ADP-ribosyl cyclases catalyze the hydrolysis of cADPR to
ADPR via generation of the same ADP-ribosyl–oxocarbenium
ion (Fig. S1, 3) (23). As BFA has two hydroxyl groups (posi-
tions 4 and 7; Fig. 1 D and E), we hypothesized that these might
react with the oxocarbenium ion intermediate. This hypothesis
was tested by producing the active derivative through the in-
cubation of [3H]-BFA with [32P]-NAD+, with rat brain mem-
branes as the source of enzyme, and analyzing the product by
HPLC. The results showed that the NAD+ derivative contained
both [3H] and [32P] at a 1:1 ratio (Fig. S2), indicating that the
Fig. 1. ADP-ribosylation of BARS is mediated by formation of a conjugate between BFA and ADPR. (A) One-step reaction: total rat brain membrane fractions
(ME) and rat cytosol were incubated for 1 h at 37 °C with 30 μM total NAD+ (spiked with 5 μCi [32P]-NAD+), in the absence and presence of BFA (80 μg/mL).
Two-step reaction: total rat brain membrane fractions, 30 μM total NAD+ (spiked with 5 μCi [32P]-NAD+), and BFA (80 μg/mL) were combined as indicated and
incubated for 1 h at 37 °C; the membranes then were removed by centrifugation. The resulting supernatant was ultraﬁltered (Microcon YM-3) and incubated
with rat cytosol for 1 h at 37 °C. The samples were analyzed by SDS/PAGE and autoradiography. (B) Rat brain membranes, [32P]-NAD+, and BFA were in-
cubated as indicated in SI Materials and Methods. Membranes were removed by centrifugation, and the supernatants were ultraﬁltered. The resulting ﬁltrate
was loaded onto an HPLC C18 reverse-phase (RP) column and eluted with a nonlinear gradient of phosphate buffer containing tetrabutylammonium chloride
(ﬁrst column). The fractions that induced ADP-ribosylation were eluted at 100% nonlinear gradient of buffer B and recovered, lyophilized, and loaded onto
an HPLC C18 RP column for the second puriﬁcation step in the absence of tetrabutylammonium chloride. The metabolite of interest eluted at 50% buffer B
after 17 min of the gradient (second column). (C) The puriﬁed metabolite was incubated with rat brain cytosol, separated by SDS/PAGE, and analyzed by
autoradiography. (D) Molecular structure of BFA. (E) Effect of BFA analogs on ADP-ribosylation of GADPH and BARS. (F) Proposed structure of BAC.
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active derivative is a BAC. The expected mass of a product
composed of BFA and ADPR is 822 Da (see below).
To determine the BFA structural features required to induce
BAC formation, we tested several BFA analogs that were
modiﬁed at one or both of the BFA hydroxyl groups (positions
4 and 7; Fig. 1 D and E) (24). Only the BFA analogs carrying a
hydroxyl group at position 7, such as B27 (a BFA diastereoisomer)
and B18 (Fig. 1 D and E), supported the formation of BAC-like
derivatives. Importantly, however, these new types of BAC did
not react with BARS, which indicated that the structure of BFA
is required for BARS ADP-ribosylation (Fig. 1E). The metabo-
lite induced by B27 bound to GAPDH [the other less efﬁcient
substrate modiﬁed by BAC (25, 26)] to a lesser extent (Fig. 1E).
These results indicate that the hydroxyl group at position 7 of
BFA reacts with the ADP-ribosyl–oxocarbenium ion intermediate
generated by ADP-ribosyl cyclase, to form a BAC (Fig. 1F) that
binds to BARS with high efﬁciency (Fig. S3). Other BFA analogs
(i.e., those that lack the hydroxyl at position 4 or have an inverted
conﬁguration at C7) can induce the formation of BAC-like mol-
ecules with distinct features but do not bind to BARS.
BAC Binds Covalently into the NAD+-Binding Pocket of BARS. Next,
we focused on the binding of BAC to BARS. This binding must be
covalent, as it persists under denaturing SDS/PAGE conditions
(Fig. 1 A and C). We ﬁrst tested whether the whole BAC mol-
ecule binds to BARS, or whether BAC acts as an ADPR donor.
To address this point, we produced BAC using [3H]-labeled BFA.
The HPLC-puriﬁed [3H]-BAC was incubated with recombinant
BARS and examined by SDS/PAGE and a radioactivity imager.
BARS incubated with [3H]-BAC was radiolabeled, indicating
that the BARS-bound BAC contains BFA. No signal was detected
when BARS was incubated with only [3H]-BFA (Fig. S4A). We
also made use of an antibody developed against BFA to further
examine whether the whole BACmolecule (i.e., both the BFA and
ADPR portions) binds to BARS. If this were the case, the binding
of the BFA portion of BAC should be revealed by the immuno-
reactivity of modiﬁed BARS to this anti-BFA antibody. Puriﬁed
recombinant BARS was incubated with BFA or BAC and treated
for immunoblotting. The anti-BFA antibody immunoreacted with
BARS after incubation with BAC (Fig. S4 B and C), conﬁrming
the notion that the entire BAC binds to BARS (see below).
Notably, this also was the case for the derivative produced using
cADPR bound to BARS (Fig. S4D). In addition, we used
a complementary approach based on the ability of the protein
module macrodomain to recognize ADP-ribose (27). As shown
in Fig. S4E, the macrodomain recognized BARS, indicating that
ADP-ribose was present in the modiﬁed BARS. These collective
data suggest that BARS-bound BAC contains both the BFA and
ADPR moieties.
To characterize this reaction further, recombinant BARS
was incubated with BAC and subjected to both MALDI-TOF
mass spectrometry (MS) and MS/MS and liquid chromatogra-
phy (LC)-MS analyses. The MALDI analysis showed that after
binding to BAC, BARS has a molecular mass of 822 Da greater
than that of the control BARS protein. This shift corresponds to
the calculated mass of BAC, conﬁrming the above predictions
that BAC consists of a BFA molecule conjugated with an ADPR,
presumably through its hydroxyl group at position 7 (Fig. 1F).
Secondly, the fragmentation data indicated that BAC is bound to
the His304 residue (Fig. S5A). In conﬁrmation of this ﬁnding, the
BARS point mutant His304Ala was not modiﬁed by BAC, whereas
several other mutants in the BARS dinucleotide binding site (see
below) showed covalent BAC binding levels indistinguishable from
those of wild-type BARS (Fig. S5B).
Then, to investigate the structural details of the covalent
binding of BAC to BARS, we used a molecular modeling ap-
proach and our previous knowledge of the BARS crystal struc-
ture to ﬁt a BAC molecule into the well-characterized NAD(H)
Rossmann fold in BARS (28), based on the common ADP
molecular framework shared by NAD(H) and BAC (Fig. 2 A
and B). In the crystal structure of the BARS–NAD(H) complex
[Protein Data Bank (PDB) ID code 1HKU], a protein cavity
lined by residues Tyr65, His66, Arg86, Gly88, Ser89, Gly90, Asp92,
Ser113, Thr117, Arg255, His304, Trp307, Ser313, and Met316 is
occupied by the NAD(H) nicotinamide moiety (28). This cavity
may host the BFA moiety of BAC (Fig. 2). Analysis of the po-
larity/hydrophobicity side-chain distribution within the cavity
suggests that the orientation of the BFA moiety of BAC would
be with its C3 atom close to the imidazole ring of His304 (Fig.
2C). According to this model, the His304 side chain might be
hydrogen bonded to Glu284 [as found in the crystal structure of
the BARS-NAD(H) complex], which would assist His304 during
a nucleophilic attack on the BFA C3 atom. Furthermore, the
BFA carbonylic O1 and hydroxylic O4 atoms would be located in
two positively charged pockets lined by residues His66/Arg86
and Arg86/Arg255, respectively (Fig. 2C). In particular, the
Arg86 side chain is positioned to form a hydrogen bond with the
carbonyl group of BFA, thus polarizing the carbon–oxygen bond,
whereas Arg255 binds the carboxylate moiety of BFA, helping
position the BFA moiety of BAC correctly in the active site. The
BFA plane is further kept in the correct orientation for catalysis
by a stacking interaction with the Trp307 side chain. As the C3
atom of BFA is strongly polarized as a result of the electron-
attractor effect of the nearby conjugated electrophilic carbonyl
(lactone) group and of the 4-hydroxy group (29), a rational ex-
planation of the strong and speciﬁc binding of BAC to BARS is
that the ADPR portion of BAC is involved in recognition and
binding to the BARS nucleotide-binding cleft, whereas the C3
atom of the BFA portion is involved in covalent binding to
His304, which may act as an electron donor in a nucleophilic
reaction (Michael addition). This hypothesis is supported by the
Fig. 2. Model of BAC binding to BARS. View of the BARS nucleotide binding
site with (A) the NAD(H) cofactor bound (PDB ID code 1HKU) and (B) the
modeled BAC molecule. Position 7 of BFA, where the conjugation between
ADPR and BFA takes place to form BAC, is indicated. (C) Stereoview of the
BAC binding site. Residues relevant to BAC interaction and to catalysis are
shown in stick representation (white and green, respectively) and labeled.
Hydrogen bonds are indicated as dashed lines, whereas the nucleophilic
attack between His304 and the C3 atom of BAC is indicated by an arrow.
Hydrogen atoms are not shown.
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observation that the BAC formed using B18, which is charac-
terized by a diffused conjugated double bond that ranges from
C1 to C4, did not bind covalently to BARS (Fig. 1F). In addition,
molecules with a coumarinic moiety, which we previously showed
to act as speciﬁc inhibitors of ADP-ribosylation (30), and which
are known to bind in the Rossmann fold (31), behaved as com-
petitive inhibitors for the binding of BAC to BARS (Fig. S6).
Collectively, these ﬁndings and the MS data in Fig. S5 A and B
support our computational model of the BARS modiﬁcation by
BAC and indicate that (i) BAC ﬁts into the BARS Rossmann
fold with high afﬁnity and speciﬁcity and (ii) its BFA portion is
involved in covalent binding to His304 through a nucleophilic-
reaction.
BAC Is Synthesized in Living Cells by the ADP-Ribosyl Cyclase CD38.As
the above data suggest that BAC is synthesized by an ADP-
ribosyl cyclase, we focused on the membrane-bound ADP-ribosyl
cyclase CD38, a mammalian enzyme responsible for synthesizing
the Ca2+-releasing signaling metabolite cADPR (32). To test for
a role of CD38, we performed the in vitro assay for BAC for-
mation using whole membrane fractions prepared from control
HeLa cells that do not express CD38 (CD38−) and from HeLa
cells stably transfected with a vector for CD38 expression
(CD38+) (33), with analysis by SDS/PAGE and autoradiography.
As shown in Fig. 3A, only the membranes obtained from CD38+
HeLa cells supported the formation of BAC, which demon-
strates that this ADP-ribosyl cyclase is indeed involved in the
synthesis of BAC. Whether the mechanism of BAC formation
involves a covalent or a noncovalent CD38–ADP-ribosyl–oxo-
carbenium ion intermediate remains undetermined. According
to some authors, this intermediate is covalently bound to CD38
(21), whereas others have suggested that it is not covalently at-
tached (22).
We then tested whether BAC formation and binding to
BARS by CD38 also occurs in living cells. For this, the CD38+
HeLa cells were transfected with YFP-BARS or the YFP-BARS
His304Ala point mutant, and incubated with NAD+ in the ab-
sence or presence of BFA. These treatments did not induce
major alterations in the subcellular localization of CD38, which
remained prevalently localized at the plasma membrane (Fig.
S7). The cells were lysed, YFP-BARS was immunoprecipitated
with an anti-BARS antibody, and the samples were subjected to
SDS/PAGE and immunoblotting with an anti-BFA antibody.
Strikingly, BAC bound to YFP-BARS in CD38+ HeLa cells,
whereas the YFP-BARS His304Ala mutant was not modiﬁed, as
expected (Fig. 3B). The reaction was very efﬁcient, as more than
90% of the overexpressed wild-type BARS was modiﬁed by BAC
after 4 h of incubation. BAC formation also was induced by
addition of cADPR to the medium (Fig. S8). Importantly, BARS
expressed in the CD38+ HeLa cells incubated in the absence of
exogenously added NAD+ (and of other possible sources of
NAD+, e.g., serum) also showed BAC binding to BARS, al-
though the fraction of the modiﬁed BARS and the rate of the
reaction were lower than in cells supplemented with NAD+ (Fig.
3C). Together, these ﬁndings show that CD38 also can catalyze
the formation of BAC in intact cells in the absence of exogenously
added NAD+.
CD38 is an ectoenzyme, and its catalytic domain is localized
extracellularly (32–34). It has been proposed that the conversion
of extracellular NAD+ to cADPR and the subsequent cADPR
inﬂux is mediated by the juxtaposition of two CD38 monomers,
which results in a catalytically active channel (35). Although the
extracellular NAD+ concentration is low in cell culture, this
concentration may be increased locally by connexin 43 hemi-
channels, which translocate NAD+ to the extracellular space
(36, 37). To test whether BAC can be produced outside the
cells, control CD38− and CD38+ HeLa cells were incubated with
BFA in the presence of NAD+. Then, the various media were
collected and incubated with recombinant BARS, and protein
modiﬁcation was monitored with the anti-BFA antibody. BARS
showed BAC binding when incubated with the medium from the
BFA-treated CD38+ HeLa cells (Fig. S9A). Thus, BAC can be
produced extracellularly. To investigate whether extracellularly
generated BAC can cross the plasma membrane, CD38− HeLa
cells were transfected with YFP-BARS and treated with BFA
and NAD+, as well as with a recombinant catalytically active
soluble portion of CD38, to generate BAC in the medium. As
expected, the addition of recombinant CD38 supported the ex-
tracellular formation of BAC (Fig. S9B), but YFP-BARS was not
modiﬁed (Fig. S9C), which indicates that the BAC generated in
the medium cannot cross the plasma membrane. As a further
test, CD38+ cells were incubated with medium containing pu-
riﬁed BAC. Again, no modiﬁcation of BARS was observed (Fig.
S9D), indicating that extracellular BAC cannot cross the plasma
membrane, even in cells that express CD38.
Together, these data indicate that CD38 is required for the in-
tracellular translocation of BAC, although it might not necessarily
transport BAC itself. The exact mechanism of this translocation
remains to be determined.
BAC Affects the Oligomerization/Conformation of BARS and Inhibits
the Binding of BARS with Interactors Involved in Fission. Next, we
investigated the mechanism through which the binding of BAC
to BARS affects the activity of BARS (20, 25). It has been pro-
posed that BARS can switch between its nuclear corepression
activity and its membrane-ﬁssion activity depending on its bind-
ing with two cofactors, NAD(H) and acyl-CoA. Under this model,
NAD(H) promotes a “closed dimeric/tetrameric conformation”
and enhances the binding of BARS to cellular and viral tran-
scriptional repressors (28, 38), whereas the binding of palmitoyl-
CoA to BARS promotes an “open monomeric conformation” of
BARS, which appears to promote membrane ﬁssion (11). Re-
cently, 14-3-3γ and p21-activated kinase 1 (PAK1) were shown to
be essential BARS interactors involved in the ﬁssion of post-Golgi
Fig. 3. CD38 can support BAC synthesis in intact cells. (A) Total membrane
fractions from control (CD38−) and CD38+ HeLa cells were incubated for 2 h
at 37 °C with recombinant His-BARS and 30 μM total NAD+ (spiked with 5 μCi
[32P]-NAD+), in the absence and presence of BFA (80 μg/mL). The samples
were analyzed by SDS/PAGE and autoradiography (AR [32P]); total BARS
levels were analyzed by Western blotting. (B) CD38+ HeLa cells were trans-
fected with wild-type YFP-BARS (BARS WT) or YFP-BARS with the His304
point mutation (BARS H304A). After 24 h, the cells were treated with 80 μg/
mL BFA for 4 h at 37 °C, in the presence of 5 mM extracellular NAD+. YFP-
BARS was immunoprecipitated using an anti-BARS antibody, and the mod-
iﬁed protein was revealed using an anti–BFA-speciﬁc antibody. (B, Lower)
Total BARS levels are shown. (C) CD38+ HeLa cells were transfected with YFP-
BARS. After 24 h, the cells were treated with 80 μg/mL BFA for 1 h or 4 h at
37 °C, in the presence or absence of exogenously added 5 mM NAD+, as
indicated. YFP-BARS was immunoprecipitated from total lysates using an
anti-BARS antibody, and the modiﬁed protein was revealed using an anti–
BFA-speciﬁc antibody. (C, Lower) Total levels of BARS are shown.
Colanzi et al. PNAS | June 11, 2013 | vol. 110 | no. 24 | 9797
CE
LL
BI
O
LO
G
Y
carriers and of macropinosomes (9, 10). We investigated whether
BAC binding can selectively inhibit BARS interactions with mo-
lecular partners involved in membrane ﬁssion. To test this hy-
pothesis, we performed an in vitro pull-down assay (9). The
preincubation of immobilized, His-tagged BARS with BAC
strongly impaired the ability of BARS to bind to GST-tagged
14-3-3γ and GST-tagged PAK1 (Fig. 4A) (9, 10). Instead, the
interaction with E1A, a known cofactor in transcription cor-
epression (28), was not affected by BAC (Fig. 4A). Based on
these ﬁndings, we postulated that the covalent binding of BAC to
BARS would irreversibly lock BARS in a closed dimeric/tetra-
meric conformation, which would be inactive in ﬁssion (11). We
tested this hypothesis by ﬁrst examining whether the covalent
binding of BAC to BARS can alter the oligomerization state of
BARS. Rat brain cytosol was incubated with control buffer, or with
NAD+ or BAC, and subjected to gel-ﬁltration chromatography.
The native protein eluted in two main peaks, which approxi-
mately corresponded to the 50-kDa and 170-kDa molecular
weight markers, suggesting a BARS conformation compatible
with an equilibrium between the open monomeric and closed
dimeric (and/or tetrameric) states (25). The incubation with
NAD+ increased the proportion of BARS detected at a mo-
lecular mass of 158 kDa (Fig. 4B); after incubation with BAC,
BARS was found exclusively in fractions corresponding to an
apparent molecular mass >158 kDa (Fig. 4B). This indicates
that the covalent binding of BAC to BARS alters its oligo-
merization/interaction state by favoring the tetramer, most
probably as a result of changes in the BARS conformation (28).
As BAC cannot cross the plasma membrane, we investigated
the effects of BAC on the ﬁssion-inducing activity of BARS in an
in vitro assay in permeabilized cells that reconstitutes the BARS-
dependent mitotic ﬁssion and fragmentation of the Golgi com-
plex, a process required for entry into mitosis (13). Incubation of
permeabilized cells with mitotic cytosol induced ﬁssion of the
Golgi complex into dispersed fragments, as already reported
(Fig. 4C) (13). When BAC was added to mitotic cytosol under
conditions resulting in exhaustive binding of BARS to BAC (Fig.
S3), Golgi ﬁssion/fragmentation was strongly inhibited (Fig. 4C),
indicating that the covalent binding of BAC to BARS inhibits the
ability of BARS to induce mitotic Golgi fragmentation. Then, to
test the effect of BAC in living cells, we induced the ADP-
ribosylation of BARS by microinjecting puriﬁed BAC in G2-
blocked HeLa cells and monitored the effect of this treatment on
mitotic entry, which depends tightly on Golgi fragmentation (13).
As shown in Fig. 4D, the injection of BAC caused a strong im-
pairment of entry into mitosis, in line with the expected effect of
the inhibition of BARS on Golgi fragmentation.
Together, these data indicate that the binding of BAC to
BARS favors an oligomeric conformation of BARS whereby
BARS cannot interact with the proteins necessary for BARS-
induced ﬁssion, and that this reaction therefore inhibits the
ability of BARS to support mitotic ﬁssion of the Golgi complex
and mitotic entry.
Discussion
In this study, we describe a two-step mechanism that underlies
the modiﬁcation of BARS by BFA, and we test the functional
role of this reaction. The ﬁrst reaction step is catalyzed by the
ADP-ribosyl cyclase CD38 and leads to the formation of BAC,
a BFA–ADP-ribose conjugate. The mechanism of BAC formation
is based on the catalytic mechanism of conversion of NAD+ to
cADPR. This involves cleavage of the NAD+ nicotinamide–ribose
bond and the subsequent formation of an enzyme-stabilized ADP-
ribosyl–oxocarbenium ion intermediate with good electrophilic
properties, which reacts with the hydroxyl groups in position 7 of
BFA to form BAC (Fig. S1). Notably, again in common with the
mechanism of conversion of NAD+ to cADPR, the synthesis of
BAC occurs at the external cell surface, where BAC is translated
during synthesis into the cell cytosol, as has been proposed to
occur for cADPR synthesis and inﬂux (35).
The second step is the covalent binding of BAC into the
BARS NAD(H)-binding pocket (the Rossmann fold) (28). As
shown in the model in Fig. 2, a compelling explanation of this
reaction is that the C3 atom of BFA in BAC is positioned close
to the imidazole ring of His304 of the BARS-binding pocket, and
it undergoes nucleophilic attack by His304. The reaction is
assisted by the hydrogen bond between His304 and Glu284 (Fig.
2 B and C). Notably, this binding mechanism is in agreement
with the known similarities between BARS and D2-hydroxy acid
dehydrogenases (28), in which the structurally equivalent His/
Glu(Asp)/Arg triad functions as the center for substrate binding
and dehydrogenase activity. Here, the His residue is postulated
to be the acid/base catalyst, with the Glu/Asp residue helping to
lower the His pKa to stabilize it in an unprotonated state. The
Fig. 4. BAC affects the interactions of BARS with its partners involved in
ﬁssion. (A) In vitro GST pull-down assay. His-BARS was preincubated with
HPLC-puriﬁed BAC to induce BAC binding. After 3 h, equimolar amounts of
GST, GST-E1A, GST-14/3/3γ or GST-PAK1 were added to the mixture and in-
cubated for another 2 h at 4 °C. The GST-tagged proteins were recovered
and eluted. The samples were subjected to SDS/PAGE and immunoblotted
with antibodies directed against GST or BARS. (B) Gel-ﬁltration patterns of
rat brain cytosol were treated as indicated. The fractions were separated by
SDS/PAGE and immunoblotted with an anti-BARS antibody. (C) Golgi frag-
mentation assay. Digitonin-permeabilized normal rat kidney cells were in-
cubated with mitotic cytosol preincubated with HPLC-puriﬁed BAC (BAC) or
buffer alone. Golgi fragmentation was evaluated and quantiﬁed by immu-
noﬂuorescence using an antibody against giantin (13). (D) Quantiﬁcation of
the mitotic index of cells grown on coverslips and arrested in G2 phase of the
cell cycle, as described in SI Materials and Methods. One hour before the G2
block release, the cells were microinjected with BAC or buffer alone (both
mixed previously with dextran-FITC as a tracer of microinjection). The cells
were ﬁxed 40 min after the G2 block release and stained with the DNA dye
Hoechst 33342. Quantiﬁcation data are means ± SD from three independent
experiments, each carried out in duplicate. More than 200 cells were
microinjected for each condition. *P = 0.02.
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Arg residue is proposed to polarize the substrate 2-hydroxyl
group for catalysis (28).
This reaction between BAC and BARS is exquisitely selective,
as BAC binds covalently exclusively to the Rossmann fold of
BARS, but not to that of other dehydrogenases, with the partial
exception of GAPDH, in which the reaction is orders of mag-
nitudes less efﬁcient. Such remarkable selectivity suggests that
this reaction might have a role in the toxicity of BFA, perhaps in
cell types or organisms expressing high levels of CD38 or other
similar ADP-ribosyl cyclases. Indeed, the modiﬁcation of BARS
by BAC may impair the ﬁssion-inducing activity of BARS re-
quired for mitotic Golgi fragmentation, an effect that may result
in a potent and prolonged block in G2 of the cell cycle, and
eventually in cell apoptosis (12, 13).
Perhaps more important, the fact that BFA may lead to the
covalent binding of BAC to BARS has implications for cancer
treatment. Based on the structural data now available on the
mechanism of this binding (this study) and on the binding of BFA
to the ARF–GTPase exchange factor (39), it now is possible to
design BFA analogs with increased selectivity toward the forma-
tion of BAC-modiﬁed BARS, and with no or strongly reduced
effects on the ARF–GTPase exchange factor. This provides a
strategy for generating BFA analogs with selective pharmacolog-
ical effects on the cell cycle. Such analogs would be relevant for
the treatment of tumors characterized by high levels of CD38
expression and, hence, high rates of BAC synthesis, such as mul-
tiple myelomas (40, 41).
Materials and Methods
Unless otherwise speciﬁed, all reagents were from Sigma–Aldrich. [32P]-β-NAD+
was from PerkinElmer. The anti-BARS antibody (BC3) was produced as de-
scribed previously (9). The anti-CD38 antibody (IB4) was kindly provided by
Fabio Malavasi (University of Turin, Turin, Italy). Keyhole limpet hemocyanin
and cyclin dependent kinase 1 inhibitor RO-3306 were from Calbiochem. Cell
culture reagents were from Gibco/Invitrogen. The TransIT-LT1 reagent was
from Mirus Bio LLC. Additional materials and methods are presented in SI
Materials and Methods.
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